INZY
NASDAQInozyme Pharma Inc.
Website
News25/Ratings8
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inozyme Pharma Inc.SCHEDULE 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)
- SECSEC Form 15-12G filed by Inozyme Pharma Inc.15-12G - Inozyme Pharma, Inc. (0001693011) (Filer)
- INSIDERSVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERCOO Winton Matthew closing all direct ownership in the company (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERDirector Bolte Axel closing all direct ownership in the company (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERSEC Form 4 filed by Director Sullivan Lynne Marie4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERCEO & Chairman Treco Douglas A closing all direct ownership in the company (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERSEC Form 4 filed by Director Hopfner Robert Lorne4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- SECSEC Form EFFECT filed by Inozyme Pharma Inc.EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form EFFECT filed by Inozyme Pharma Inc.EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form 25-NSE filed by Inozyme Pharma Inc.25-NSE - Inozyme Pharma, Inc. (0001693011) (Subject)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form POS AM filed by Inozyme Pharma Inc.POS AM - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form POS AM filed by Inozyme Pharma Inc.POS AM - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECInozyme Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update8-K - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECAmendment: SEC Form SC 14D9/A filed by Inozyme Pharma Inc.SC 14D9/A - Inozyme Pharma, Inc. (0001693011) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by Inozyme Pharma Inc.SC TO-T/A - Inozyme Pharma, Inc. (0001693011) (Subject)
- PRBioMarin Announces Completion of Acquisition of InozymeSAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha
- INSIDERCOO Winton Matthew was granted 14,355 shares, increasing direct ownership by 194% to 21,743 units (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERCEO & Chairman Treco Douglas A was granted 2,815 shares, increasing direct ownership by 7% to 43,861 units (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)